Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19803146 | 0.94 | KDM4E (0.31) | TSHRHTT | |
| SCHEMBL19803147 | 0.85 | PIM1 (0.32) | — | |
| SCHEMBL19803142 | 0.84 | MAOB (0.30) | — | |
| SCHEMBL17424836 | 0.83 | TSHR (0.43) | TSHRHTTCYP2D6CYP3A4CYP2C19 | |
| SCHEMBL246647 | 0.83 | CYP2D6 (0.38) | TSHRHTTCYP2D6CYP3A4CYP2C19 | |
| SCHEMBL11121197 | 0.80 | ALDH1A1 (0.43) | TSHRHTTCYP2D6CYP1A2 | |
| SCHEMBL22068835 | 0.77 | KDM4E (0.36) | TSHRHTTCYP2D6CYP3A4CYP2C19 | |
| SCHEMBL22769465 | 0.75 | KDM4E (0.32) | TSHRHTT | |
| SCHEMBL11135987 | 0.75 | KDM4E (0.32) | TSHRHTT | |
| SCHEMBL18154850 | 0.73 | ALDH1A1 (0.33) | TSHRHTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484857-B1 | CATALYST FOR CURABLE COMPOSITIONS COMPRISING HEXAHYDROTRIAZIN STRUCTURAL UNITS | SIKA TECH AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-20190240649-A1 | CATALYST FOR CURABLE COMPOSITIONS CONTAINING HEXAHYDROTRIAZINE STRUCTURAL UNITS | SIKA TECHNOLOGY AG (CH) | 2019-08-08 | — | — | US | disclosed |
| WO-2018015344-A1 | CATALYST FOR CURABLE COMPOSITIONS CONTAINING HEXAHYDROTRIAZINE STRUCTURAL UNITS | SIKA TECHNOLOGY AG (CH) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240649-A1 | CATALYST FOR CURABLE COMPOSITIONS CONTAINING HEXAHYDROTRIAZINE STRUCTURAL UNITS | GMNN, GEMIN5, ODC1 | TSHR 4314/4885HTT 1484/4885CYP2D6 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.